Envoy Medical Statistics
Total Valuation
Envoy Medical has a market cap or net worth of $45.97 million. The enterprise value is $27.10 million.
| Market Cap | 45.97M |
| Enterprise Value | 27.10M |
Important Dates
The next estimated earnings date is Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Envoy Medical has 77.19 million shares outstanding. The number of shares has increased by 177.04% in one year.
| Current Share Class | 77.19M |
| Shares Outstanding | 77.19M |
| Shares Change (YoY) | +177.04% |
| Shares Change (QoQ) | +50.92% |
| Owned by Insiders (%) | 30.83% |
| Owned by Institutions (%) | 13.57% |
| Float | 43.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 222.07 |
| Forward PS | 124.24 |
| PB Ratio | 12.44 |
| P/TBV Ratio | 12.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 130.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.22.
| Current Ratio | 1.73 |
| Quick Ratio | 1.56 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -49.75 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -86.53% |
| Return on Invested Capital (ROIC) | -842.11% |
| Return on Capital Employed (ROCE) | -207.08% |
| Weighted Average Cost of Capital (WACC) | 15.50% |
| Revenue Per Employee | $4,404 |
| Profits Per Employee | -$605,468 |
| Employee Count | 47 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.51 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.54% in the last 52 weeks. The beta is 1.95, so Envoy Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.95 |
| 52-Week Price Change | -25.54% |
| 50-Day Moving Average | 0.70 |
| 200-Day Moving Average | 0.69 |
| Relative Strength Index (RSI) | 33.81 |
| Average Volume (20 Days) | 113,086 |
Short Selling Information
The latest short interest is 497,969, so 0.65% of the outstanding shares have been sold short.
| Short Interest | 497,969 |
| Short Previous Month | 529,130 |
| Short % of Shares Out | 0.65% |
| Short % of Float | 1.15% |
| Short Ratio (days to cover) | 8.98 |
Income Statement
In the last 12 months, Envoy Medical had revenue of $207,000 and -$28.46 million in losses. Loss per share was -$0.51.
| Revenue | 207,000 |
| Gross Profit | -608,000 |
| Operating Income | -23.43M |
| Pretax Income | -23.40M |
| Net Income | -28.46M |
| EBITDA | -23.13M |
| EBIT | -23.43M |
| Loss Per Share | -$0.51 |
Balance Sheet
The company has $19.68 million in cash and $810,000 in debt, with a net cash position of $18.87 million or $0.24 per share.
| Cash & Cash Equivalents | 19.68M |
| Total Debt | 810,000 |
| Net Cash | 18.87M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 3.69M |
| Book Value Per Share | 0.05 |
| Working Capital | 9.28M |
Cash Flow
In the last 12 months, operating cash flow was -$21.53 million and capital expenditures -$178,000, giving a free cash flow of -$21.71 million.
| Operating Cash Flow | -21.53M |
| Capital Expenditures | -178,000 |
| Depreciation & Amortization | 303,000 |
| Net Borrowing | -879,000 |
| Free Cash Flow | -21.71M |
| FCF Per Share | -$0.28 |
Margins
| Gross Margin | -293.72% |
| Operating Margin | -11,319.32% |
| Pretax Margin | -11,304.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Envoy Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -177.04% |
| Shareholder Yield | -177.04% |
| Earnings Yield | -85.53% |
| FCF Yield | -47.23% |
Analyst Forecast
The average price target for Envoy Medical is $2.17, which is 263.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.17 |
| Price Target Difference | 263.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 231.13% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Envoy Medical has an Altman Z-Score of -20.79 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.79 |
| Piotroski F-Score | 2 |